S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:NBEV

NewAge - NBEV Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.09
▼
$0.36
52-Week Range
N/A
Volume
2.58 million shs
Average Volume
4.66 million shs
Market Capitalization
$12.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NewAge Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Reduce
Based on 1 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
3/28/22 to 3/28/23		1 Month Ago
2/26/22 to 2/26/23		3 Months Ago
12/28/21 to 12/28/22		1 Year Ago
3/28/21 to 3/28/22
Consensus Rating
Reduce
Reduce
Reduce
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$6.00
Predicted UpsideN/AN/AN/A185.04% Upside
Get NewAge Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NBEV and its competitors with MarketBeat's FREE daily newsletter.

NBEV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBEV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NewAge Stock vs. The Competition

TypeNewAgeConsumer Staples CompaniesS&P 500
Consensus Rating Score
1.00
2.47
2.47
Consensus RatingReduceHoldHold
Predicted Upside793.28% Upside22.46% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/31/2022Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Sell
8/10/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Mcgowan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy$6.50 ➝ $6.00+185.03%
7/22/2020Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold
(Data available from 3/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NBEV Price Target - Frequently Asked Questions

What is NewAge's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for NewAge stock is Reduce based on the current 1 sell rating for NBEVthe . Learn more on NBEV's analyst rating history.

Do Wall Street analysts like NewAge more than its competitors?

Analysts like NewAge less than other Consumer Staples companies. The consensus rating for NewAge is Reduce while the average consensus rating for consumer staples companies is Hold. Learn more on how NBEV compares to other companies.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:NBEV) was last updated on 3/28/2023 by MarketBeat.com Staff